Coherus Biosciences Inc (CHRS)

$0.86

-0.02

(-2.6%)▲

Live

Performance

  • $0.86
    $0.89
    $0.86
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.68%

    Upside

    3.68%

    downward going graph
  • $0.84
    $3.73
    $0.86
    downward going graph

    2.33%

    Downside

    52 Weeks Volatility :77.48%

    Upside

    76.94%

    downward going graph

Returns

PeriodCoherus Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-48.06%
3.6%
0.0%
6 Months
-59.5%
10.2%
0.0%
1 Year
-72.28%
19.6%
0.0%
3 Years
-94.71%
16.8%
-23.0%

Highlights

Market Capitalization
97.7M
Book Value
-$0.73
Earnings Per Share (EPS)
-0.38
PEG Ratio
0.0
Wall Street Target Price
9.5
Profit Margin
-9.52%
Operating Margin TTM
-31.56%
Return On Assets TTM
-16.05%
Return On Equity TTM
-1657.06%
Revenue TTM
308.1M
Revenue Per Share TTM
2.82
Quarterly Revenue Growth YOY
10.7%
Gross Profit TTM
-58.4M
EBITDA
-142.3M
Diluted Eps TTM
-0.38
Quarterly Earnings Growth YOY
-0.75
EPS Estimate Current Year
-0.7
EPS Estimate Next Year
-0.23
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Coherus Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1004.65%

Current $0.86
Target $9.50

Company Financials

FY18Y/Y Change
Revenue
1.6M
↑ 0.0%
Net Income
-209.3M
↓ 12.11%
Net Profit Margin
-13.5K%
↑ 1852.9%
FY19Y/Y Change
Revenue
356.1M
↑ 22783.74%
Net Income
89.8M
↓ 142.91%
Net Profit Margin
25.23%
↑ 13478.89%
FY20Y/Y Change
Revenue
475.8M
↑ 33.63%
Net Income
132.2M
↑ 47.21%
Net Profit Margin
27.79%
↑ 2.56%
FY21Y/Y Change
Revenue
326.6M
↓ 31.37%
Net Income
-306.3M
↓ 331.63%
Net Profit Margin
-93.81%
↓ 121.6%
FY22Y/Y Change
Revenue
211.0M
↓ 35.37%
Net Income
-326.6M
↑ 6.63%
Net Profit Margin
-154.77%
↓ 60.96%
FY23Y/Y Change
Revenue
257.2M
↑ 21.89%
Net Income
-237.9M
↓ 27.17%
Net Profit Margin
-92.48%
↑ 62.29%
Q1 FY23Q/Q Change
Revenue
32.4M
↓ 28.48%
Net Income
-74.8M
↑ 12.88%
Net Profit Margin
-230.55%
↓ 84.48%
Q2 FY23Q/Q Change
Revenue
58.7M
↑ 81.02%
Net Income
-42.9M
↓ 42.67%
Net Profit Margin
-73.01%
↑ 157.54%
Q3 FY23Q/Q Change
Revenue
74.6M
↑ 27.0%
Net Income
-39.6M
↓ 7.53%
Net Profit Margin
-53.16%
↑ 19.85%
Q4 FY23Q/Q Change
Revenue
91.5M
↑ 22.74%
Net Income
-79.7M
↑ 100.94%
Net Profit Margin
-87.03%
↓ 33.87%
Q1 FY24Q/Q Change
Revenue
77.1M
↓ 15.8%
Net Income
102.9M
↓ 229.15%
Net Profit Margin
133.49%
↑ 220.52%
Q2 FY24Q/Q Change
Revenue
65.0M
↓ 15.68%
Net Income
-12.9M
↓ 112.56%
Net Profit Margin
-19.88%
↓ 153.37%
FY18Y/Y Change
Total Assets
99.5M
↓ 38.83%
Total Liabilities
138.1M
↑ 4.53%
FY19Y/Y Change
Total Assets
408.9M
↑ 311.12%
Total Liabilities
303.7M
↑ 119.99%
FY20Y/Y Change
Total Assets
841.6M
↑ 105.82%
Total Liabilities
560.7M
↑ 84.61%
FY21Y/Y Change
Total Assets
679.3M
↓ 19.29%
Total Liabilities
581.6M
↑ 3.73%
FY22Y/Y Change
Total Assets
480.8M
↓ 29.22%
Total Liabilities
618.3M
↑ 6.3%
FY23Y/Y Change
Total Assets
629.6M
↑ 30.94%
Total Liabilities
823.0M
↑ 33.12%
Q1 FY23Q/Q Change
Total Assets
402.4M
↓ 16.31%
Total Liabilities
598.9M
↓ 3.13%
Q2 FY23Q/Q Change
Total Assets
469.6M
↑ 16.69%
Total Liabilities
644.4M
↑ 7.58%
Q3 FY23Q/Q Change
Total Assets
583.8M
↑ 24.32%
Total Liabilities
717.4M
↑ 11.33%
Q4 FY23Q/Q Change
Total Assets
629.6M
↑ 7.85%
Total Liabilities
823.0M
↑ 14.73%
Q1 FY24Q/Q Change
Total Assets
763.5M
↑ 21.27%
Total Liabilities
845.4M
↑ 2.72%
Q2 FY24Q/Q Change
Total Assets
674.9M
↓ 11.62%
Total Liabilities
759.0M
↓ 10.22%
FY18Y/Y Change
Operating Cash Flow
-159.3M
↓ 20.48%
Investing Cash Flow
-1.2M
↓ 73.1%
Financing Cash Flow
105.4M
↓ 49.02%
FY19Y/Y Change
Operating Cash Flow
28.4M
↓ 117.8%
Investing Cash Flow
-12.7M
↑ 971.72%
Financing Cash Flow
89.4M
↓ 15.23%
FY20Y/Y Change
Operating Cash Flow
154.1M
↑ 443.63%
Investing Cash Flow
-14.4M
↑ 13.11%
Financing Cash Flow
223.9M
↑ 150.58%
FY21Y/Y Change
Operating Cash Flow
-37.4M
↓ 124.28%
Investing Cash Flow
-138.4M
↑ 861.11%
Financing Cash Flow
51.9M
↓ 76.83%
FY22Y/Y Change
Operating Cash Flow
-241.1M
↑ 544.17%
Investing Cash Flow
-166.9M
↑ 20.55%
Financing Cash Flow
54.3M
↑ 4.72%
Q1 FY23Q/Q Change
Operating Cash Flow
-68.7M
↓ 31.24%
Investing Cash Flow
17.5M
↓ 113.49%
Financing Cash Flow
3.8M
↓ 42.3%
Q2 FY23Q/Q Change
Operating Cash Flow
-38.9M
↓ 43.38%
Investing Cash Flow
41.4M
↑ 136.02%
Financing Cash Flow
54.3M
↑ 1328.1%

Technicals Summary

Sell

Neutral

Buy

Coherus Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Coherus Biosciences Inc
Coherus Biosciences Inc
-15.11%
-59.5%
-72.28%
-94.71%
-95.4%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Coherus Biosciences Inc
Coherus Biosciences Inc
NA
NA
0.0
-0.7
-16.57
-0.16
NA
-0.73
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Coherus Biosciences Inc
Coherus Biosciences Inc
Buy
$97.7M
-95.4%
NA
-9.52%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Coherus Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 91.52M → 64.97M (in $), with an average decrease of 15.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 102.87M → -12.92M (in $), with an average decrease of 112.6% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 158.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 139.5%

Institutional Holdings

  • BlackRock Inc

    10.20%

  • Vanguard Group Inc

    9.20%

  • Rubric Capital Management LP

    9.03%

  • Temasek Holdings Ltd.

    5.05%

  • Kohlberg Kravis Roberts & Co LP

    2.64%

  • Citadel Advisors Llc

    2.47%

Company Information

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Organization
Coherus Biosciences Inc
Employees
246
CEO
Mr. Dennis M. Lanfear
Industry
Health Technology

Discover More

FAQs